Total Payments
$7,872
2024 Payments
$2,702
Companies
36
Transactions
170
Medicare Patients
10,969
Medicare Billing
$485,295
Payment Breakdown by Category
Research$5,764 (73.2%)
Food & Beverage$2,107 (26.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5,764 | 36 | 73.2% |
| Food and Beverage | $2,107 | 134 | 26.8% |
Payments by Type
Research
$5,764
36 transactions
General
$2,107
134 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $2,341 | 1 | $0 (2024) |
| Gilead Sciences, Inc. | $1,251 | 15 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $1,194 | 10 | $0 (2017) |
| ABBVIE INC. | $1,024 | 12 | $0 (2024) |
| Novo Nordisk Inc | $376.04 | 24 | $0 (2024) |
| GlaxoSmithKline, LLC. | $266.75 | 16 | $0 (2024) |
| PFIZER INC. | $253.02 | 21 | $0 (2024) |
| Abbott Laboratories | $126.63 | 6 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $121.91 | 7 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $93.21 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,702 | 23 | Eli Lilly and Company ($2,341) |
| 2023 | $363.43 | 20 | Xeris Pharmaceuticals, Inc. ($41.40) |
| 2022 | $416.91 | 23 | GlaxoSmithKline, LLC. ($70.00) |
| 2021 | $234.43 | 16 | Novo Nordisk Inc ($47.88) |
| 2020 | $55.38 | 5 | Welch Allyn ($12.77) |
| 2019 | $2,369 | 38 | Gilead Sciences, Inc. ($1,251) |
| 2018 | $243.63 | 18 | Novo Nordisk Inc ($70.54) |
| 2017 | $1,487 | 27 | Regeneron Pharmaceuticals, Inc. ($1,194) |
All Payment Transactions
170 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.08 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Gastroenterology | ||||||
| 11/04/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: Inflammation | ||||||
| 10/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: Gastroenterology | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,341.00 | Research |
| Study: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | ||||||
| 09/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: RESPIRATORY | ||||||
| 08/27/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: Endocrinology | ||||||
| 08/21/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: VACCINES | ||||||
| 08/07/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Gastroenterology | ||||||
| 08/05/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: Diabetes | ||||||
| 07/31/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $10.95 | General |
| Category: Diabetes | ||||||
| 07/22/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: Diabetes | ||||||
| 05/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: NEUROSCIENCE | ||||||
| 04/26/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Diabetes | ||||||
| 04/23/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: VACCINES | ||||||
| 04/19/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Endocrinology | ||||||
| 03/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: Diabetes | ||||||
| 02/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: Diabetes | ||||||
| 02/07/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: RESPIRATORY | ||||||
| 02/01/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/01/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $7.94 | General |
| Category: Obesity | ||||||
| 01/22/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Diabetes | ||||||
| 01/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/07/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $14.43 | General |
| Category: Cardiovascular | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | Eli Lilly and Company | $2,341 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | Gilead Sciences, Inc. | $1,251 | 15 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK | Regeneron Pharmaceuticals, Inc. | $1,194 | 10 |
| M16-100 | AbbVie, Inc. | $978.37 | 10 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 2,762 | 4,211 | $354,039 | $131,729 |
| 2022 | 44 | 2,866 | 4,313 | $318,813 | $125,041 |
| 2021 | 40 | 2,717 | 4,373 | $312,137 | $129,025 |
| 2020 | 37 | 2,624 | 4,011 | $264,827 | $99,500 |
Total Patients
10,969
Total Services
16,908
Medicare Billing
$485,295
Procedure Codes
154
All Medicare Procedures & Services
154 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 212 | 437 | $100,510 | $32,046 | 31.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 192 | 192 | $63,360 | $22,781 | 36.0% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 170 | 171 | $39,672 | $12,935 | 32.6% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 37 | 37 | $17,649 | $10,145 | 57.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 103 | 159 | $25,122 | $8,636 | 34.4% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 223 | 400 | $12,800 | $5,169 | 40.4% |
| 91320 | Sarscv2 vac 30mcg trs-suc im | Office | 2023 | 38 | 38 | $14,326 | $4,625 | 32.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 230 | 431 | $9,051 | $4,399 | 48.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 58 | 58 | $4,930 | $4,172 | 84.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 237 | 514 | $6,888 | $4,158 | 60.4% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 189 | 189 | $9,450 | $3,166 | 33.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 211 | 411 | $7,809 | $3,082 | 39.5% |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | Office | 2023 | 55 | 55 | $4,400 | $2,498 | 56.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 76 | 76 | $3,572 | $2,161 | 60.5% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 68 | 112 | $4,480 | $1,811 | 40.4% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 86 | 179 | $4,117 | $1,630 | 39.6% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 38 | 38 | $4,370 | $1,365 | 31.2% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 36 | 36 | $1,692 | $1,024 | 60.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $4,511 | $1,009 | 22.4% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 21 | 23 | $2,231 | $898.55 | 40.3% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 48 | 89 | $1,869 | $769.08 | 41.1% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 76 | 98 | $3,136 | $527.47 | 16.8% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 77 | 98 | $1,274 | $473.53 | 37.2% |
| 81003 | Automated urinalysis test | Office | 2023 | 139 | 212 | $1,272 | $455.40 | 35.8% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 11 | 11 | $1,606 | $344.70 | 21.5% |
About Dr. John Kirby, M.D
Dr. John Kirby, M.D is a Internal Medicine healthcare provider based in Jefferson City, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2005. The National Provider Identifier (NPI) number assigned to this provider is 1275539835.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Kirby, M.D has received a total of $7,872 in payments from pharmaceutical and medical device companies, with $2,702 received in 2024. These payments were reported across 170 transactions from 36 companies. The most common payment nature is "" ($5,764).
As a Medicare-enrolled provider, Kirby has provided services to 10,969 Medicare beneficiaries, totaling 16,908 services with total Medicare billing of $485,295. Data is available for 4 years (2020–2023), covering 154 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Jefferson City, TN
- Active Since 06/28/2005
- Last Updated 09/27/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1275539835
Products in Payments
- PRALUENT ALIROCUMAB INJECTION (Biological) $1,194
- Androgel (Drug) $978.37
- Ozempic (Drug) $153.99
- XIFAXAN (Drug) $121.91
- Rybelsus (Drug) $98.60
- CHANTIX (Drug) $93.40
- FreeStyle Libre Pro (Device) $84.71
- ENTRESTO (Drug) $78.20
- TRELEGY ELLIPTA (Drug) $74.05
- SHINGRIX (Biological) $70.63
- Dexcom G6 Transmitter (Medical Supply) $69.11
- MOUNJARO (Drug) $66.81
- NURTEC ODT (Drug) $59.11
- Victoza (Drug) $57.23
- BEXSERO (Biological) $56.33
- Kerendia (Drug) $52.16
- ELIQUIS (Drug) $48.75
- FreeStyle Libre blood glucose Flash Monitoring System (Device) $41.92
- GVOKE HYPOPEN (Drug) $41.40
- WAKIX (Drug) $40.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Jefferson City
Dr. Alan Rauba, M.d, M.D
Internal Medicine — Payments: $921,314
Internal Medicine $921,314
Dr. Christopher Case, M.d, M.D
Internal Medicine — Payments: $193,448
Internal Medicine $193,448
Dr. Thomas Schneider, M.d, M.D
Internal Medicine — Payments: $17,202
Internal Medicine $17,202
Dr. Stephen Sides, D.o, D.O
Internal Medicine — Payments: $11,660
Internal Medicine $11,660
Lorenzo Mcknelly, D.o, D.O
Internal Medicine — Payments: $10,588
Internal Medicine $10,588
Simin Ovais, Do, DO
Internal Medicine — Payments: $5,849
Internal Medicine $5,849